CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Guo, Wenchang ^a   Liu, Ruiwu ^a   Bhardwaj, Gaurav ^a   Ma, Ai Hong ^a   Changou, Chun ^a   Yang, Joy C ^a   Li, Yuanpei ^a   Feng, Caihong ^a   Luo, Yan ^a   Mazloom, Anisha ^a   Sanchez, Eduardo ^a   Wang, Yan ^a   Huang, Wenzhe ^a   Patterson, Randen ^a   Evans, Christopher P ^b   Lam, Kit S ^a   Kung, Hsing Jien ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c National Health Research Institutes NHRI   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (DIBENZO[B,D]FURAN 2 YL) 7 PHENYL 1 [3 (PIPERIDIN 1 YL)PROPYL] 1H IMIDAZO[4,5 G]QUINOXALIN 6(5H) ONE; CTA 095; ETK PROTEIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SRC INHIBITOR; SRC PROTEIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; WOUND HEALING;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BENZOFURANS; BINDING SITES; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; QUINOXALINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881581558     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070910     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics. CA Cancer J Clin. 2008. 58: 71-96.
2. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 318: 287-90.
3. Xue LY, Qiu Y, He J, Kung HJ, Oleinick NL, (1999) Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene. 18: 3391-8.
4. Chang YM, Kung HJ, Evans CP, (2007) Nonreceptor tyrosine kinases in prostate cancer. Neoplasia. 9: 90-100.
5. Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, et al. (2000) Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol. 20: 2043-54.
6. Chau CH, Chen KY, Deng HT, Kim KJ, Hosoya K, et al. (2002) Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene. 21: 8817-29.
7. Chen R, Kim O, Li M, Xiong X, Guan JL, et al. (2001) Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nature cell biology. 3: 439-44.
8. Guo L, Zhou Y, Sun Y, Zhang F, (2010) Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. Eur J Cancer. 46: 636-41.
9. He Y, Luo Y, Tang S, Rajantie I, Salven P, et al. (2006) Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. The Journal of clinical investigation. 116: 2344-55.
10. Zhang Z, Zhu W, Zhang J, Guo L, (2011) Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation. Cancer Biol Ther. 11: 690-8.
11. Dai B, Kim O, Xie Y, Guo Z, Xu K, et al. (2006) Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 66: 8058-64.
12. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, et al. (2011) Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 19: 498-511.
13. Mizushima N, (2007) Autophagy: process and function. Genes & development. 21: 2861-73.
14. Xie Z, Klionsky DJ Autophagosome formation: core machinery, (2007) adaptations (2007) Nature cell biology. 9: 1102-9.
15. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, et al. (2009) Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 69: 700-8.
16. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, et al. (2010) Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes & cancer. 1: 40-9.
17. Guo W, Liu R, Ono Y, Ma AH, Martinez A, et al. (2012) Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol Pharmacol. 82: 938-47.
18. Halgren TA, (1996) Merck molecular force field. 1. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17: 490-519.
19. Soding J, Biegert A, Lupas AN, (2005) The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res 33: W244-248.
20. Soding J, (2005) Protein homology detection by HMM-HMM comparison. Bioinformatics 21: 951-960.
21. Grosdidier A, Zoete V, Michielin O, (2011) SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39: W270-277.
22. Grosdidier A, Zoete V, Michielin O (2011) Fast docking using the CHARMM force field with EADock DSS. J Comput Chem.
23. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
24. Zoete V, Cuendet MA, Grosdidier A, Michielin O, (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32: 2359-2368.
25. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38.
26. Laskowski RA, Swindells MB, (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51: 2778-2786.
27. Lou Q, Wu J, Lam KS, (1996) A protein kinase assay system for both acidic and basic peptides. Anal Biochem. 235: 107-9.
28. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, et al. (1997) ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene. 15: 2705-16.
29. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, et al. (2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2: 58-61.
30. Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM, (2012) Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. 55: 4539-50.
31. Pan S, An P, Zhang R, He X, Yin G, et al. (2002) Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 22: 7512-23.
32. Li Y, Xiao K, Luo J, Xiao W, Lee JS, et al. (2011) Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials. 32: 6633-45.
33. Kato J, Li Y, Xiao K, Lee JS, Luo J, et al. (2012) Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm. 9: 1727-35.
34. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, et al. (1991) A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 354: 82-4.
35. McDonald OB, Chen WJ, Ellis B, Hoffman C, Overton L, et al. (1999) A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem. 268: 318-29.
36. Su GH, Sohn TA, Ryu B, Kern SE, (2000) A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60: 3137-42.
37. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5: 835-44.
38. Dai B, Chen H, Guo S, Yang X, Linn DE, et al. (2010) Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res. 70: 5587-96.
39. Wu YM, Huang CL, Kung HJ, Huang CY, (2001) Proteolytic activation of ETK/Bmx tyrosine kinase by caspases. J Biol Chem. 276: 17672-8.